Webinar

Advancing Breast Cancer Drug Development with Translational Models and Biomarker-Driven Strategies

October 20, 2026 | 11:00 AM EST / 5:00 PM CET

Breast cancer drug development continues to advance across antibody-drug conjugates, targeted therapies, immuno-oncology combinations, and precision medicine approaches. As programs become more biomarker-driven, researchers need preclinical platforms that support rapid screening, translational relevance, and confident model selection across diverse breast cancer subtypes.

Crown Bioscience offers a broad breast cancer portfolio with over 300+ models spanning patient-derived organoids, PDX, CDX, syngeneic, tumor homograft, and cell line-based systems. These platforms are supported by biomarker datasets that help researchers evaluate therapeutic response, investigate mechanisms of sensitivity and resistance, and prioritize models for preclinical development.

In this webinar, Crown Bioscience experts Mariusz Madej, PhD and David Vallerand, PhD, will discuss how integrated breast cancer model systems can support oncology drug discovery from early in vitro screening through in vivo efficacy studies and translational strategy.

Mariusz will focus on Crown Bioscience’s breast cancer organoid platforms, including patient-derived and PDX-derived organoids designed for scalable, assay-ready screening workflows. David will discuss complementary in vivo and ex vivo platforms, including PDX, CDX, syngeneic, tumor homograft, and cell line-derived systems, and how these models can be combined with biomarker data to support model selection and program decision-making.

Register Now

What You’ll Learn:

• How breast cancer organoid platforms support scalable in vitro screening and responder analysis
• How patient-derived and PDX-derived organoids can be used to evaluate novel therapeutics, including ADCs and targeted therapies
• How PDX, CDX, syngeneic, Tumor homograft models, and cell line-based models support breast cancer efficacy studies and translational research
• How biomarker datasets, including mutation, RNA expression, copy number, fusion, HLA, and IHC data, can guide breast cancer model selection
• How breast cancer and ADC-relevant biomarkers such as ER, PR, HER2, Ki67, TROP2, B7-H4, Nectin-4, FOLR1, and HER3 can inform preclinical study design
• Key considerations for selecting breast cancer models for ADCs, targeted therapies, immuno-oncology combinations, and biomarker-driven development strategies

This session is designed for discovery, translational, and preclinical development scientists seeking integrated breast cancer model strategies that connect high-throughput screening, in vivo efficacy, and biomarker-informed decision-making.

About The Presenters:

Mariusz Madej, PhD, Director of Organoid Biology, Crown Bioscience

Mariusz Madej, PhD is the Director of Organoid Biology at Crown Bioscience, based in Leiden, Netherlands. An expert in advanced 3D cell culture systems, Mariusz oversees the development and execution of high-throughput organoid screening platforms designed to accelerate oncology drug discovery. His work specializes in scaling assay-ready patient-derived organoids and PDX-derived organoids, including highly relevant breast cancer models, to evaluate novel therapeutics such as antibody-drug conjugates and targeted therapies. Mariusz completed his advanced scientific training at the Universität Salzburg and is a frequent speaker on integrating translatable 3D tumor models into cost-effective, high-throughput drug screening workflows.

David Vallerand, PhD, Senior Director of Scientific Engagement, Europe, Crown Bioscience

David Vallerand, PhD, is the Senior Director of Scientific Engagement for Europe at Crown Bioscience. A scientist by training, he brings extensive expertise in translational research and biological drug development, spanning innovative preclinical models through clinical phases. David completed his doctoral research at Roche before holding key leadership roles across several biotechnology and pharmacology services companies. Throughout his career, he has contributed to the advancement of novel anticancer drugs in clinical development, including PEP-010 and INVAC-1. At Crown Bioscience, he works closely with commercial and research teams to help partners leverage cutting-edge scientific platforms to accelerate solid tumor and oncology drug discovery.